` 2DT (Amneal Pharmaceuticals Inc) vs DAX Index Comparison - Alpha Spread

A
2DT
vs
D
DAX Index

Over the past 12 months, 2DT has outperformed DAX Index, delivering a return of +38% compared to the DAX Index's +22% growth.

Stocks Performance
2DT vs DAX Index

Loading
2DT
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2DT vs DAX Index

Loading
2DT
DAX Index
Difference
www.alphaspread.com

Performance By Year
2DT vs DAX Index

Loading
2DT
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Amneal Pharmaceuticals Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Amneal Pharmaceuticals Inc
Glance View

Market Cap
3.1B EUR
Industry
Pharmaceuticals

Amneal Pharmaceuticals Inc., birthed from the vision of two brothers, Chirag and Chintu Patel, stands today as a formidable entity in the generic and specialty pharmaceutical sector. Emerging from its modest beginnings in 2002 in Paterson, New Jersey, Amneal has embarked on a remarkable journey of growth and innovation. The company is best known for its strong portfolio of affordable generic medicines, which span a broad range of therapeutic areas. This ensures that they provide essential medications at more accessible prices, thus fulfilling a critical role in healthcare by making necessary treatments available to wider demographics. The company leverages vertical integration and cutting-edge manufacturing facilities to maintain high efficiency, allowing it to consistently produce and distribute pharmaceuticals on a global scale. Beyond generics, Amneal has diversified its operations to include complex drug delivery systems and specialty pharmaceuticals, carving out a niche in the more profitable segments of the pharmaceutical industry. By investing in research and development, the company continues to innovate, focusing particularly on high-barrier segments such as biosimilars and injectable medications. This strategic pivot not only enhances the company’s product offerings but also positions it more robustly against market volatilities. Amneal generates revenue by manufacturing and distributing its extensive product portfolio through partnerships with both retailers and health care facilities, ensuring a steady flow of sales. The company’s dual approach of maintaining a strong base in generics while exploring specialty and complex products shines a beacon on its strategic flexibility and its commitment to sustainable growth in the ever-evolving pharmaceutical landscape.

2DT Intrinsic Value
16.43 EUR
Undervaluation 39%
Intrinsic Value
Price
A
Back to Top